Quince Therapeutics, Inc. reported on October 2, 2025, that a statement regarding the inefficacy of N-acetyl-L-leucine for patients with ataxia-telangiectasia was removed from their Investor Day Presentation due to reliance on an incorrect article; this statement should not be relied upon by investors.